BIOA
Price
$14.08
Change
+$0.87 (+6.59%)
Updated
Dec 24 closing price
Capitalization
504.84M
83 days until earnings call
Intraday BUY SELL Signals
HROW
Price
$50.16
Change
+$1.01 (+2.05%)
Updated
Dec 24 closing price
Capitalization
1.86B
89 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIOA vs HROW

Header iconBIOA vs HROW Comparison
Open Charts BIOA vs HROWBanner chart's image
BioAge Labs
Price$14.08
Change+$0.87 (+6.59%)
Volume$196.87K
Capitalization504.84M
Harrow
Price$50.16
Change+$1.01 (+2.05%)
Volume$320.89K
Capitalization1.86B
BIOA vs HROW Comparison Chart in %
BIOA
Daily Signal:
Gain/Loss:
HROW
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BIOA vs. HROW commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Buy and HROW is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (BIOA: $14.08 vs. HROW: $50.16)
Brand notoriety: BIOA and HROW are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOA: 38% vs. HROW: 53%
Market capitalization -- BIOA: $504.84M vs. HROW: $1.86B
BIOA [@Pharmaceuticals: Generic] is valued at $504.84M. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.86B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOA’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • BIOA’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, both BIOA and HROW are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOA’s TA Score shows that 3 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).

  • BIOA’s TA Score: 3 bullish, 3 bearish.
  • HROW’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BIOA is a better buy in the short-term than HROW.

Price Growth

BIOA (@Pharmaceuticals: Generic) experienced а +14.47% price change this week, while HROW (@Pharmaceuticals: Generic) price change was +13.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.58%. For the same industry, the average monthly price growth was +8.11%, and the average quarterly price growth was +22.96%.

Reported Earning Dates

BIOA is expected to report earnings on Mar 19, 2026.

HROW is expected to report earnings on Mar 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.58% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.86B) has a higher market cap than BIOA($505M). BIOA YTD gains are higher at: 143.178 vs. HROW (49.508). HROW has higher annual earnings (EBITDA): 39.4M vs. BIOA (-74.68M). BIOA has more cash in the bank: 286M vs. HROW (74.3M). BIOA has less debt than HROW: BIOA (7.13M) vs HROW (252M). HROW has higher revenues than BIOA: HROW (250M) vs BIOA (5.92M).
BIOAHROWBIOA / HROW
Capitalization505M1.86B27%
EBITDA-74.68M39.4M-190%
Gain YTD143.17849.508289%
P/E Ratio1.03N/A-
Revenue5.92M250M2%
Total Cash286M74.3M385%
Total Debt7.13M252M3%
FUNDAMENTALS RATINGS
BIOA vs HROW: Fundamental Ratings
BIOA
HROW
OUTLOOK RATING
1..100
3021
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
6938
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
3439
P/E GROWTH RATING
1..100
910
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOA's Valuation (50) in the Chemicals Specialty industry is somewhat better than the same rating for HROW (83) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is in the same range as BIOA (69) in the Chemicals Specialty industry. This means that HROW’s stock grew similarly to BIOA’s over the last 12 months.

HROW's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as BIOA (96) in the Chemicals Specialty industry. This means that HROW’s stock grew similarly to BIOA’s over the last 12 months.

BIOA's Price Growth Rating (34) in the Chemicals Specialty industry is in the same range as HROW (39) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to HROW’s over the last 12 months.

BIOA's P/E Growth Rating (9) in the Chemicals Specialty industry is in the same range as HROW (10) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOAHROW
RSI
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
N/A
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BIOA
Daily Signal:
Gain/Loss:
HROW
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITETX10.490.04
+0.38%
VY® T. Rowe Price Equity Income S2
REVCX13.250.05
+0.38%
Columbia Global Value C
WFPCX41.100.10
+0.24%
Allspring Special Mid Cap Value C
FFNIX14.41N/A
N/A
Fidelity Advisor Asset Manager 40% I
GPEOX9.97N/A
N/A
Grandeur Peak Emerg Mkts Opps Inv

BIOA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOA
1D Price
Change %
BIOA100%
+6.59%
UPC - BIOA
50%
Loosely correlated
+14.88%
TKNO - BIOA
28%
Poorly correlated
+0.24%
ASRT - BIOA
27%
Poorly correlated
-0.02%
EBS - BIOA
24%
Poorly correlated
+0.72%
HROW - BIOA
24%
Poorly correlated
+2.05%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+2.05%
AMRX - HROW
34%
Loosely correlated
+0.23%
TKNO - HROW
34%
Loosely correlated
+0.24%
VTRS - HROW
34%
Loosely correlated
+1.83%
OGI - HROW
30%
Poorly correlated
+1.15%
ASRT - HROW
30%
Poorly correlated
-0.02%
More